Craig H. Mallinckrodt1, David J. Goldstein, Michael J. Detke, Yili Lu, John G. Watkin, Pierre V. Tran. 1. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind.; PRN Consulting, Indianapolis, Ind.; the Department of Pharmacology and Toxicology and the Department of Psychiatry, Indiana University School of Medicine, Indianapolis; the Department of Psychiatry, McLean Hospital, Belmont, Mass.; the Department of Psychiatry, Harvard Medical School, Boston, Mass.; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C.
Abstract
BACKGROUND: Depression is underdiagnosed in the primary care setting. Physical symptoms such as aches, pains, and gastrointestinal disturbance are frequently associated with major depressive disorder (MDD) and are often the presenting symptoms. Duloxetine, a dual-reuptake inhibitor of serotonin and norepinephrine, may have a positive effect on physical symptoms in addition to efficacy in treating emotional symptoms of depression. METHOD:Efficacy was evaluated in 6 double-blind, placebo- and/or active comparator-controlled trials of duloxetine for patients with MDD (DSM-IV criteria). Efficacy in depression was determined primarily using the 17-item Hamilton Rating Scale for Depression (HAM-D-17). Secondary efficacy measures included subscales of the HAM-D-17 and assessment of physical symptoms. Safety evaluations included adverse events, vital signs, laboratory analyses, and electrocardiograms. Safety was evaluated by pooling the data from the MDD trials and a study of duloxetine in nondepressed patients. RESULTS:Duloxetine demonstrated significant differences from placebo on core mood symptoms, physical symptoms (e.g., back pain), and global functioning as early as week 1 of treatment. The estimated probabilities of remission in the studies that demonstrated efficacy ranged from 43% to 57%. The most frequently observed adverse events for duloxetine-treated patients included nausea, dizziness, insomnia, fatigue, and somnolence. Duloxetine did not prolong corrected QT intervals, and the rate of sustained elevations of blood pressure did not differ significantly from placebo. CONCLUSION: In these studies, duloxetine was safe and effective in the treatment of both emotional and physical symptoms of MDD. Based on dose assessments, 60 mg q.d. appears to be the optimum starting and therapeutic dose.
RCT Entities:
BACKGROUND:Depression is underdiagnosed in the primary care setting. Physical symptoms such as aches, pains, and gastrointestinal disturbance are frequently associated with major depressive disorder (MDD) and are often the presenting symptoms. Duloxetine, a dual-reuptake inhibitor of serotonin and norepinephrine, may have a positive effect on physical symptoms in addition to efficacy in treating emotional symptoms of depression. METHOD: Efficacy was evaluated in 6 double-blind, placebo- and/or active comparator-controlled trials of duloxetine for patients with MDD (DSM-IV criteria). Efficacy in depression was determined primarily using the 17-item Hamilton Rating Scale for Depression (HAM-D-17). Secondary efficacy measures included subscales of the HAM-D-17 and assessment of physical symptoms. Safety evaluations included adverse events, vital signs, laboratory analyses, and electrocardiograms. Safety was evaluated by pooling the data from the MDD trials and a study of duloxetine in nondepressed patients. RESULTS:Duloxetine demonstrated significant differences from placebo on core mood symptoms, physical symptoms (e.g., back pain), and global functioning as early as week 1 of treatment. The estimated probabilities of remission in the studies that demonstrated efficacy ranged from 43% to 57%. The most frequently observed adverse events for duloxetine-treated patients included nausea, dizziness, insomnia, fatigue, and somnolence. Duloxetine did not prolong corrected QT intervals, and the rate of sustained elevations of blood pressure did not differ significantly from placebo. CONCLUSION: In these studies, duloxetine was safe and effective in the treatment of both emotional and physical symptoms of MDD. Based on dose assessments, 60 mg q.d. appears to be the optimum starting and therapeutic dose.
Authors: S A Montgomery; J Henry; G McDonald; T Dinan; M Lader; I Hindmarch; A Clare; D Nutt Journal: Int Clin Psychopharmacol Date: 1994 Impact factor: 1.659
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Michael J Detke; Yili Lu; David J Goldstein; Robert K McNamara; Mark A Demitrack Journal: J Psychiatr Res Date: 2002 Nov-Dec Impact factor: 4.791
Authors: Susan G Ball; Durisala Desaiah; Melissa E Spann; Qi Zhang; James M Russell; Michael J Robinson; Koen Demyttenaere Journal: Prim Care Companion CNS Disord Date: 2011
Authors: Heidi K Moore; Madelaine M Wohlreich; Michael G Wilson; James C Mundt; Maurizio Fava; Craig H Mallinckrodt; John H Greist Journal: Psychiatry (Edgmont) Date: 2007-03
Authors: Arif Khan; Anjana Bose; George S Alexopoulos; Carl Gommoll; Dayong Li; Chetan Gandhi Journal: Clin Drug Investig Date: 2007 Impact factor: 2.859
Authors: James I Hudson; David G Perahia; Inmaculada Gilaberte; Fujun Wang; John G Watkin; Michael J Detke Journal: BMC Psychiatry Date: 2007-08-28 Impact factor: 3.630